Chimeric HPV11 L1 Protein for Cross-Protective VLP Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines provide limited cross-protection against multiple HPV types, requiring the inclusion of multiple HPV types to broaden protection, which increases production costs and potential safety risks due to higher immunizing doses.
Innovation Solution
A mutated HPV11 L1 protein with specific amino acid substitutions from HPV6, allowing it to induce neutralizing antibodies against both HPV11 and HPV6, thereby providing cross-protection comparable to a mixture of HPV11 and HPV6 VLPs at a single immunizing dose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple HPV types are included in vaccines to broaden protection range, then protection range is improved, but production cost increases
Solution Approach 1:
The patent creates a chimeric L1 protein that combines epitopes from multiple HPV types (HPV11 and HPV6) into a single protein structure. This single chimeric VLP vaccine provides cross-protection against both HPV types simultaneously, eliminating the need to produce and combine separate VLPs for each HPV type, thereby reducing production cost while maintaining broad protection range.
Solution Approach 2:
The patent merges the L1 protein sequences of different HPV types to create a chimeric protein that contains immunogenic epitopes from both HPV11 and HPV6. By combining multiple HPV type specificities into one chimeric VLP construct, the vaccine achieves multi-type protection through a single production process, reducing manufacturing complexity and cost.
2Adaptability or versatility
If multiple HPV types are included in vaccines to broaden protection range, then protection range is improved, but safety risk increases due to higher immunizing dose
Solution Approach 1:
The chimeric L1 protein is designed to elicit neutralizing antibodies against multiple HPV types through a single immunizing dose. The integrated epitopes from HPV11 and HPV6 in the chimeric structure enable simultaneous immune recognition of both virus types, achieving broad protection without requiring increased dosage that would compromise safety.
3Ease of manufacture
If a single HPV type VLP is used, then production cost is reduced, but protection range is limited
Solution Approach 1:
The chimeric L1 protein incorporates specific immunogenic epitopes from different HPV types at strategic positions within the protein structure. By placing conserved and type-specific epitopes in appropriate locations, the single chimeric VLP maintains structural integrity while presenting multiple HPV type antigens, achieving broad protection without compromising production simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated HPV11 L1 protein offers significant cross-protection against HPV11 and HPV6, reducing the need for multiple HPV types in vaccines, enhancing protection range while minimizing production costs and safety concerns.
Implementation Method 1
Major capsid protein L1 of HPV has the characteristic of self-assembling into hollow Virus-Like Particle (VLP)
Data Source
Figure 1
Figure 2A~2F
Figure 3A~3F
AI summary
Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV11 and HPV6), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also disclosed is use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.